Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G  by Ledoux, Dominique et al.
Heparin-like dextran derivatives as well as glycosaminoglycans inhibit
the enzymatic activity of human cathepsin G
Dominique Ledoux, Didier Merciris, Denis Barritault, Jean-Pierre Caruelle
Laboratoire de Recherche sur la Croissance Cellulaire, la Re¤paration et la Re¤ge¤ne¤ration Tissulaires, CNRS FRE-2412, Universite¤ Paris XII,
Avenue du Ge¤ne¤ral de Gaulle, 94000 Cre¤teil, France
Received 25 November 2002; revised 8 January 2003; accepted 9 January 2003
First published online 27 January 2003
Edited by Beat Imhof
Abstract Some synthetic dextran derivatives that mimic the
action of heparin/heparan sulfate were previously shown to in-
hibit neutrophil elastase and plasmin. Here we report that these
derivatized dextrans also inhibit cathepsin G (CatG). Dextran
containing carboxymethyl and benzylamide groups (RG1150) as
well as those containing carboxymethyl, sulfate and benzyl-
amide groups (RG1192), were the most e⁄cient inhibitors of
CatG activity. RG1192 and RG1150 bind CatG with a Ki of
0.11 and 0.17 nM, respectively, while carboxymethylated sul-
fated dextran (RG1503) as well as heparin, heparan sulfate and
dermatan sulfate bind CatG with a 7- to 30-fold lower a⁄nity.
Variation of Ki with ionic strength indicates that ionic interac-
tions account for 26% of the RG1503^CatG binding energy,
while binding of RG1192 or RG1150 to CatG is mainly gov-
erned by non-electrostatic interactions. This, together with the
fact that these compounds both protect ¢bronectin and laminin
against CatG-mediated degradation, suggest that speci¢c dex-
tran derivatives can contribute to the regulation of CatG activ-
ity.
4 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cathepsin G (CatG) is one of the major serine proteinases
found in an active form within neutrophils and monocytes [1].
CatG has a number of physiological functions which take
place during in£ammation following tissue injury, and include
degradation of phagocytosed proteins, neutrophil migration
and extracellular matrix (ECM) remodeling [1]. In vitro,
CatG is able to cleave a wide variety of ECM components
such as type IV collagen, laminin, ¢bronectin, elastin and
proteoglycans [1]. These ¢ndings thus point out an important
role for CatG in ECM remodeling during tissue degeneration
and repair.
We have previously elaborated on and investigated a new
family of polysaccharides, derived from dextran by chemical
substitutions and namely regenerating agents (RGTA). The
controlled and sequential chemical substitutions of functional
groups such as carboxymethyl, sulfate and/or benzylamide
along the dextran molecule allowed us to obtain a family of
dextran derivatives with di¡erent chemical structures and bio-
logical activities. We have shown that dextran containing car-
boxymethyl, sulfate and benzylamide groups (RG1192 com-
pound) can stimulate tissue repair in various in vivo wound-
healing models such as cutaneous wound [2], cranial bone
defect [3], infarcted myocardium [4], ischemic skeletal muscle
[5] and colic ulceration [6]. In addition, we have just reported
that carboxymethylated sulfated dextran (RG1503 compound)
can also act as a tissue repair agent by both enhancing bone
formation and reducing gingival in£ammation in a hamster
model of periodontitis [7]. In contrast, dextran substituted
only with carboxymethyl (RG1100 compound) as well as
those containing carboxymethyl and benzylamide groups
(RG1150 compound) did not display in vivo tissue repair
activity [8], thus pointing out the bene¢cial contribution of
sulfate groups with respect to the in vivo biological activity
of these biopolymers. In vitro experiments have, moreover,
revealed that RG1503 and RG1192 could act as mimics of
heparin/heparan sulfate with regard to their ability to interact
with, stabilize and protect various heparin binding growth
factors against proteolytic degradation ([9,10] and Rouet, V.
et al. Heparan sulfate mimetics enhance VEGF165 activities,
manuscript in preparation). In addition, RG1192 and to a
lesser extent RG1503, have been shown to directly inhibit
the enzymatic activity of neutrophil elastase [11] and plasmin
[12], and to protect matrix proteins from proteolytic degrada-
tion. Based on their in vitro properties, we propose that
RGTA molecules such as RG1192 and RG1503 improve re-
generation because they increase the bioavailability of growth
factors and can modify certain proteinase activities during the
various steps of normal wound healing.
We present here data that support this mechanism of action
of RGTA through the in vitro inhibition of CatG enzymatic
activity.
2. Materials and methods
2.1. Materials
The substrates succinyl-Ala2-Pro-Phe-p-nitroanilide (Suc-Ala2-Pro-
Phe-pNa) and succinyl-Ala2-Pro-Phe-thiobenzylester (Suc-Ala2-Pro-
Phe-SBzl) came from Bachem (Budendorf, Switzerland). Human
CatG was purchased from ICN (Irvine, CA, USA) and was active
site-titrated with titrated K1-PI [13]. 5,5P-dithiobis(2-nitrobenzoic
acid), human ¢bronectin, Engelbreth^Holm^Swarm mouse sarcoma
laminin, polyclonal rabbit anti-¢bronectin or laminin Ig, heparan sul-
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fate (average Mr 60,000), chondroitin 4-sulfate (average Mr 17 000
Da), chondroitin 6-sulfate (average Mr 32 000 Da), and dermatan
sulfate (average Mr 25 000 Da) were obtained from Sigma (St Louis,
MO, USA). Porcine intestine heparin (average Mr 12 000 Da) was
kindly provided by M. Petitou from Sano¢ (France). The average
molecular weights (Mr) of these glycosaminoglycans (GAG) were de-
termined by size exclusion chromatography using gel ¢ltration col-
umns (Shodex, Japan). Horseradish peroxidase-conjugated goat anti-
rabbit Ig was from Diagnostic-Pasteur (Marne la Coquette, France).
Immobilon P and electrochemiluminescence were purchased from
Millipore Corporation (Saint-Quentin en Yvelines, France) and
Superblock0 blocking bu¡er was from Pierce (Rockford, IL, USA).
RGTA are water-soluble dextran derivatives obtained by controlled
and sequential substitutions of CH2COONa (CM), SO3Na (Su) and/
or CH2CONHCH2C6H5 (CMBn) groups on the OH residues of glu-
cose units. Synthesis, structure, chemical characterization and average
Mr determination of these polymers have been previously described in
detail [12]. Brie£y, compound RG1100 (average Mr 51 000 Da) was
synthesized from dextran T40 (average Mr 37 000 Da; Pharmacia,
Sweden) by carboxymethylation of OH residues. Compound
RG1503 (average Mr 72 000 Da) was synthesized from RG1100 by
O-sulfonation of the free OH residues. Compound RG1150 (average
Mr 72 000 Da) was synthesized from a carboxymethylated dextran
by amidation of the carboxylate residues with benzylamine (NH2-
CH2C6H5). Compound RG1192 (average Mr 78 000 Da) was ob-
tained by O-sulfonation of RG1150. The chemical characterization
of all dextran derivatives was based on the degree of substitution
(d.s.) of each individual group per glucosidic unit. The d.s. values
of each group for the di¡erent polymers were as follows: CM=0.6
for RG1100; CM=0.6 and Su=1.1 for RG1503; CM=0.8 and
CMBn=0.4 for RG1150; CM=0.8, Su= 0.3 and CMBn=0.4 for
RG1192. Measure of the reductive sugars content indicates that dex-
tran T40 contains an average of 250 glucosidic units per chain. The
RGTA polymers present very low anti-coagulant activity, i.e. less than
10 IU/mg as compared to 180 IU/mg for heparin [9].
2.2. Enzymatic methods
Enzymatic kinetics were monitored with a thermostated Labsystem
iEMS spectrophotometer on-line with a PC. The progress curves were
recorded for 1^10 min, depending upon the reaction velocity and less
than 5% of the substrate was hydrolyzed during the rate measure-
ment. The hydrolysis of Suc-Ala2-Pro-Phe-pNa was recorded at 405
nm (O405 = 9650 M31 cm31) while that of Suc-Ala2-Pro-Phe-SBzl was
monitored at 412 nm in the presence of 5,5P-dithiobis(2-nitrobenzoic
acid) (0.2 mM), a coupling reagent that transforms benzylthiol, the
product of substrate hydrolysis, into a yellow-colored compound
(O412 = 13 600 M31 cm31) [14]. Substrates and 5,5P-dithiobis(2-nitro-
benzoic acid) were dissolved in N,N-dimethyl-formamide whose ¢nal
concentration in the reaction media was 3% (v/v). The bu¡er was 50
mM HEPES, 100 mM NaCl, pH 7.4, 25‡C, unless otherwise stated.
The e¡ect of various polymers on the CatG enzymatic activity was
determined by reacting constant concentration of enzyme with in-
creasing concentrations of polymers for 5 min and measuring the
residual enzymatic activity with a synthetic substrate. The equilibrium
dissociation constant (Ki) values and their standard errors were calcu-
lated by non-linear regression using the integral equation editor of the
GraphPad Prism software (San Diego, CA, USA).
2.3. Western blot analysis of ¢bronectin or laminin proteolytic
fragments
CatG (500 nM) and polymers were incubated at 37‡C for 30 min in
50 mM HEPES pH 7.4, 100 mM NaCl, 0.01% Triton X-100 prior to
addition of 50 ng of ¢bronectin (3.8 nM) or 100 ng of laminin (3.8
nM). Following 1 h of incubation, proteins were separated by sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE)
under reducing conditions and then electrophoretically transferred
overnight at 4‡C to Immobilon-P membrane in 25 mM Tris pH 8.3,
192 mM glycine. Membranes saturated with Superblock0 blocking
bu¡er were incubated with polyclonal rabbit anti-human ¢bronectin
Ig or polyclonal rabbit anti-mouse laminin Ig at 1:1000 dilution in
phosphate-bu¡ered saline containing 0.02% (v/v) Tween-20 and 0.3%
Superblock0 blocking bu¡er. Antibodies were detected by using
horseradish peroxidase-conjugated goat anti-rabbit IgG and electro-
chemiluminescence according to the manufacturer’s recommenda-
tions.
3. Results and discussion
3.1. E¡ect of GAG and RGTA on the amidolytic activity
of CatG
Fig. 1A shows the e¡ect of di¡erent GAG on the amidolytic
activity of CatG. As previously reported [13,15], heparin in-
hibits partially the enzymatic activity of CatG, indicating that
heparin tightly binds the enzyme to form complexes that are
partially active on substrate. We showed, moreover, that hep-
aran sulfate and dermatan sulfate also exhibit an inhibitory
action on CatG characterized for both polymers by 40% of
residual enzymatic activity. In contrast, chondroitin 4-sulfate
and chondroitin 6-sulfate did not a¡ect the activity of CatG
even for concentrations greater than 0.5 WM.
We have previously shown that some dextran derivatives,
namely RGTA, acted as mimics of heparin with regard to
their ability to inhibit neutrophil elastase [11]. Based on this
functional homology, we then evaluated their capacity to
modulate the enzymatic activity of CatG. Fig. 1B shows that
dextran substituted with carboxymethyl groups (RG1100)
weakly a¡ected the activity of CatG. Following O-sulfona-
tion, the resulting derivatized polymer (RG1503) showed
an inhibitory potential toward CatG with 40% of residual
enzymatic activity. When hydrophobic benzylamide groups
were additionally coupled to a carboxymethylated dextran
(RG1150) or to a carboxymethylated sulfated dextran
(RG1192), a more potent inhibitory activity was observed,
characterized by an inhibition of more than 90% of the
CatG enzymatic activity (Fig. 1B).
3.2. Study of the mechanism of CatG inhibition by RGTA
and GAG
Heparin, heparan sulfate, dermatan sulfate and all RGTA
tested form complexes with CatG that remain partially active
on synthetic substrate. This type of inhibition may be de-
scribed by Scheme 1 where E, S, and I stand for enzyme,
substrate, and polymers, respectively, Ki is the equilibrium
dissociation constant of the enzyme^inhibitor complex, n is
the number of enzyme molecules bound per molecule of poly-
mer, and K and L are dimensionless numbers representing the
change in a⁄nity (K) and the change in the catalytic rate
constant (L).
Scheme 1.
With tight-binding reversible inhibitors, inhibition depends
upon the total enzyme concentration since the concentration
of the bound inhibitor [EI] is no longer negligible with respect
to that of total inhibitor concentration [I]0 [16]. Such a mech-
anism has been already described for the inhibition of CatG
by heparin [13]. We therefore analyzed whether RGTA mol-
ecules as well as other GAG behaved as tight-binding inhib-
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itors by measuring the inhibition of CatG using di¡erent en-
zyme concentrations. As shown in Fig. 2, inhibition pro¢le of
CatG by RG1192 was modi¢ed by an increase of the enzyme
concentration [E]0 ; IC50 = 0.3 nM and 0.6 nM for [E]0 = 1.5
nM and 3 nM, respectively. Similar results were obtained with
RG1503, RG1150, as well as with heparin, heparan sulfate
and dermatan sulfate (data not shown), indicating that all
these polymers acted as tight-binding inhibitors of CatG.
Use was made of this particular behavior to measure the bind-
ing stoichiometry of each polymer^CatG complex using high
reactant concentration of enzyme ([E]0/KiE100) to ensure
pseudo-irreversible binding of CatG to inhibitor [16]. In the
case of the RG1192^CatG complex (see Fig. 2, inset), the
inhibitor/enzyme titration curve intercepted the abscissa at
[I]0/[E]0 = 0.25, indicating that about four molecules of CatG
bound to one molecule of RG1192 (n=4). The n values for
other polymer^CatG complexes could also be determined in
this way (Table 1).
With lower CatG concentrations, the inhibition curves were
concave so that the data could be used to calculate Ki by non-
linear regression analysis (see Fig. 1A for GAG, Fig. 1B for
RG1503 and Fig. 2 for RG1192). Since these polymers be-
haved as tight-binding inhibitors, Ki was calculated from the
complex steady-state rate equation derived by Szedlacsek et
al. [17] which takes into account both the tight-binding char-
acter and the incompleteness of inhibition (equation not
shown). Table 1 summarizes the parameters characterizing
the inhibition of CatG by heparin, heparan sulfate and der-
matan sulfate. As previously described [13,15], heparin inhib-
ited CatG according to a reversible, tight-binding, hyperbolic
Fig. 1. E¡ects of di¡erent GAG (A) and RGTA (B) on the enzy-
matic activity of CatG. Increasing concentrations of chondroitin
4-sulfate (E, A), chondroitin 6-sulfate (F, A), heparan sulfate (a,
A), heparin (b, A) or dermatan sulfate (R, A) as well as RG1503
(b, B), RG1100 (E, B), RG1150 (R, B), RG1192 (a, B) were
added to CatG (30 nM) at pH 7.4, 25‡C, and the residual enzy-
matic activity was measured with Suc-Ala2-Pro-Phe-pNa (2 mM).
Abscissa, [GAG] or [RGTA], nanomolar concentrations of GAG or
RGTA in the assay multiplied by the number of binding sites, re-
spectively. Ordinates, vi/v0, initial rate in the presence of inhibitor/
initial rate in its absence.
Fig. 2. Determination of the equilibrium dissociation constant and
the stoichiometry of the RG1192/CatG complex at pH 7.4 and
25‡C. The CatG concentrations ([E]0) were 1.5 nM (R), 3 nM (a)
and 30 nM (b, inset). The substrate was Suc-Ala2-Pro-Phe-SBzl (80
WM) for [E]0 = 1.5 and 3 nM and Suc-Ala2-Pro-Phe-pNa (2 mM) for
[E]0 = 30 nM. The inset shows a titration experiment, which allows
determining the RG1192/CatG binding stoichiometry. [RG1192],
nanomolar concentration of RG1192 in the assay. vi/v0, see legend
to Fig. 1.
Table 1
Parameters characterizing the inhibition of CatG by RGTA and
GAG
Polymer K L Ki (M) n
RG1503a 1.4 0.43 (1.2T 0.3)U1039 22
RG1150b 7 0.7 (0.17T 0.02)U1039 4
RG1192b 7 0.9 (0.11T 0.04)U1039 4
Heparina 1.4 0.27 (0.8T 0.2)U1039 3
Heparan sulfatea 1.4 0.36 (3.0T 0.4)U1039 12
Dermatan sulfatea 1.5 0.42 (0.8T 0.2)U1039 5
Ki and its standard error were calculated by non-linear regression
analysis and the given value corresponds to the best estimate ob-
tained from one ¢t curve among three independent experiments for
each polymer. Standard deviation between the three experiments is
less than 15%. The bu¡er was 50 mM HEPES, 100 mM NaCl, pH
7.4, 25‡C.
aK, L and Ki were measured with Suc-Ala2-Pro-Phe-pNa (2 mM)
(Km =2.3 mM, kcat = 3.2 s31) and [CatG]= 25 nM whereas n was de-
termined with [CatG]= 500 nM and the same substrate.
bK, L and Ki were measured with Suc-Ala2-Pro-Phe-SBzl (80 WM)
(Km =50 WM, kcat = 30 s31) and [CatG]= 3 nM whereas n was deter-
mined with [CatG]= 30 nM and Suc-Ala2-Pro-Phe-pNa (2 mM) as
substrate.
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mixed-type mechanism (06 L6 1 and Ks 1). Here we show
that heparan sulfate and dermatan sulfate also inhibit CatG
according to the same mechanism. Analysis of the inhibition
parameters reported in Table 1 reveals that heparin and der-
matan sulfate bind CatG with identical a⁄nities (0.8 nM)
while heparan sulfate displays a 4-fold lower a⁄nity. This
result is surprising since it does not well correlate with the
negative charge content of the polysaccharide studied. Indeed,
dermatan sulfate and heparan sulfate both contain two neg-
ative charges per disaccharide unit (one carboxylate and
Vone sulfate group) while one disaccharide unit of heparin
bears an average of 3.5 negative charges (one carboxylate and
V2.5 sulfate groups) [18]. These results suggest that the poly-
saccharide^CatG interaction is not strictly dependent on
charge density and that glycosidic linkage, type of saccharide
present, and molecular weight may also be important in dis-
playing the interacting groups of the polysaccharide in a pro-
ductive manner. However, the fact that the poorly sulfated
chondroitin 4- and 6-sulfates (V0.15 sulfate group/disaccha-
ride unit) do not bind to CatG suggests an essential role of
negatively charged groups in the enzyme/polysaccharide com-
plex formation, most probably by establishing ionic interac-
tions between the two partners (see the paragraph below). The
12-kDa heparin chain used in this study was shown to bind
three molecules of CatG and, in a more general way, results
indicated that stoichiometry increased with the increasing
average Mr of the polysaccharides studied; n=3, 5, 12 for
heparin (Mr 12 000 Da), dermatan sulfate (Mr 25 000 Da)
and heparan sulfate (Mr 60 000 Da), respectively. Considering
that one disaccharide unit of heparin has a molecular mass of
about 0.6 kDa [18], the 12-kDa heparin chain used here is
composed of about 20 disaccharide units. Hence, we may
conclude that 13^14 glucosidic units of heparin were required
for a 1:1 heparin:CatG binding stoichiometry. It is notewor-
thy that this size of binding site is similar to the one involved
in the binding of a 5.1-kDa heparin fragment to CatG [15] as
well as in the binding of heparin with leukocyte elastase [19],
mucus proteinase inhibitor [20] or secretory leukocyte pro-
tease inhibitor [21].
Table 1 also described the parameters characterizing the
inhibition of CatG by RG1503, a carboxymethylated sulfated
dextran, and by RG1150 and RG1192, two RGTA com-
pounds containing hydrophobic benzylamide groups. First,
it can be seen that RG1503 bound CatG with a Ki value in
the nanomolar range and inhibited its enzymatic activity ac-
cording to a hyperbolic mixed-type mechanism. Moreover,
one molecule of RG1503 interacted with 22 molecules of
CatG (n=22), indicating that about 12 glucosidic units of
RG1503 were involved in the binding of one CatG molecule.
These results, compared to those described above, suggest that
this carboxymethylated sulfated dextran inhibits the CatG
enzymatic activity according to a heparin-like mechanism. In-
terestingly, it appears also from Table 1 that RG1150 and
RG1192 thoroughly di¡er from RG1503 in their ability to
inhibit the CatG activity. Indeed, (i) they have a 10-fold high-
er a⁄nity for CatG than RG1503 and, (ii) they form with
CatG a 1:4 binding stoichiometry (n=4), a 5-fold lower value
than the one determined for the RG1503^CatG complex. If
we assume that all RGTA contain the same content of gluco-
sidic units per chain, the di¡erence in stoichiometry observed
between benzylamided and non-benzylamided RGTA could
be interpreted as a di¡erence in displaying their interacting
groups in a productive manner toward the protein, that is
to say a di¡erence in their three-dimensional conformation.
This idea is supported by preliminary studies (D. Papy, per-
sonal communication) using computer analysis, which showed
that benzylamided dextran (RG1150 and RG1192) can form
globular-like structures in aqueous solution, while non-ben-
zylamided dextran (RG1503) preferentially adopts a linear
and helicoidal-like conformation. In any event, these results
clearly indicate that chemical substitution of polysaccharides
by both anionic and hydrophobic residues leads to a very
e⁄cient class of CatG inhibitor, represented here by
RG1150 and RG1192 compounds. Moreover, this class of
molecules constitutes to our knowledge, one of the most
powerful reversible inhibitors of CatG, characterized by Ki
values lower or far lower than those previously reported in-
cluding natural GAG (our results and [15,22]), DNA [23],
proteins [24,25] as well as synthetic molecules [26^28].
3.3. In£uence of ionic strength on the Ki of the RGTA^CatG
complexes
CatG is a very basic protein (pIV12) characterized by an
extremely large number of positively charged residues (34 ar-
ginines, four lysines), 36 of which are not compensated by
neighboring counter charges [29]. Most of the arginine resi-
dues are arranged on the surface site opposite to the active
site of the protein, although three of them are located in the
immediate vicinity of the active site [29]. It was previously
shown that binding of heparin to CatG was governed by
electrostatic interactions [15,19]. In order to determine
whether ionic interactions are also involved in its binding to
RG1503, RG1150 or RG1192, the ionic strength dependence
of the equilibrium dissociation constants Ki was analyzed ac-
cording to the theory of macromolecule^polyelectrolyte inter-
actions [30,31]. The theory predicts that binding of a protein
(CatG) to a polyelectrolyte (polyanionic polymer) in the pres-
ence of a counterion (Naþ) will result in the stoichiometry
Fig. 3. In£uence of ionic strength on the equilibrium dissociation
constant Ki of RG1503^CatG (F), RG1150^CatG (a) and
RG1192^CatG (b) complexes measured at pH 7.4 and 25‡C (50
mM HEPES bu¡er). Ki values were plotted as a function of [NaCl]
(0.1^0.4 M) in accordance to Eq. 1 and the data were analyzed by
linear regression. Ki were measured with Suc-Ala2-Pro-Phe-SBzl (80
WM) and [CatG]= 3 nM for RG1150 and RG1192 and with Suc-
Ala2-Pro-Phe-pNa (2 mM) and [CatG]= 25 nM for RG1503.
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release of Naþ from the polyanionic polymer. At equilibrium,
the process may be described as follows:
where Z is the number of purely ionic interactions formed
between CatG and the polymer, which result in the displace-
ment of Zi-bound Naþ from the polymer and i represents
the fraction of Naþ bound to the polymer per unit charge. A
value of i=0.9 has been experimentally determined1 for all
RGTA compounds, thus indicating that about 90% of their
negatively charged groups (sulfates and/or carboxylates) were
ionized. The observed equilibrium dissociation constant, Ki,
characterizing the equilibrium detailed in Scheme 2 is related
to the non-ionic equilibrium dissociation constant, Kiðnon-ionicÞ,
through the relationship:
log K i ¼ log K iðnon-ionicÞ þ Zi log½Naþ ð1Þ
where Kiðnon-ionicÞ may be considered as the dissociation con-
stant for non-ionic protein^polymer interactions so that the
contribution of ionic interactions to the binding at 0.1 M
NaCl may be calculated [30]. Fig. 3 shows that the plots of
log Ki vs. log [Naþ] are linear for the three CatG^RGTA
complexes but only the one corresponding to the CatG^
RG1503 complex has a positive slope, as predicted by Eq.
1. This indicates that the contribution of ionic interactions
in the di¡erent RGTA^enzyme complexes depends upon the
nature of the RGTA compound, i.e. the nature of the chem-
ical groups substituted to the dextran.
In the case of RG1503, the value of Z calculated from the
positive slope and using i=0.9 was found to be 2.30T 0.02.
This indicates that about two ionic interactions are involved
in the RG1503^enzyme binding. For [NaCl] = 1 M, log
Ki = log Kiðnon-ionicÞ and Kiðnon-ionicÞ =0.22 WM. At 0.1 M
NaCl, the ionic strength used throughout this study Ki was
1.2 nM (see Table 1) while Kiðnon-ionicÞ =0.22 WM. Comparison
of the logarithms of these numbers indicates that V26% of
the RG1503^CatG binding free energy is derived from purely
ionic interactions at pH 7.4 and 25‡C. These results are very
similar to those reported by Ermolie¡ et al. [32] which indi-
cate that about 22% of the heparin^CatG binding energy is
due to ionic interactions and that an average of two ionic
interactions were required for a 1:1 heparin:CatG binding
stoichiometry. On the other hand, chemical characterization
of RG1503 indicates that one glucosidic unit of this polymer
bears an average of 1.7 negatively charged group (sulfate+
carboxylate; see Section 2). Assuming that 90% of them are
ionized (i=0.9), we may conclude that one molecule of
RG1503 carries about 380 negatively charged groups that
are able to interact with the positively charged groups of
CatG. Hence, considering the n and Z binding parameters
calculated above, it appears that about 11% of the ionized
groups of RG1503 are involved in the binding of CatG. In
comparison, the binding of heparin to CatG involves about
9% of the polysaccharide’s charged groups [15,32]. All togeth-
er, these results as well as those derived from Table 1 con¢rm
that this RGTA compound behaves as a real functional mi-
metic of heparin in term of inhibitor of the amidolytic activity
of CatG.
When the same experiments were performed with RG1150
Fig. 4. E¡ect of RG1503, RG1150 and RG1192 on the CatG-mediated ¢bronectin and laminin proteolysis. CatG and the di¡erent polymers
were preincubated at 37‡C prior to addition of laminin (A) or ¢bronectin (B). Samples were then analyzed under reducing conditions by SDS^
PAGE followed by Western blotting assays with antibodies to human ¢bronectin or mouse laminin. A: Laminin (3.8 nM) and CatG (500 nM)
were incubated without (lane 2) or with 100 nM of RG1503 (lane 3), RG1150 (lane 4) or RG1192 (lane 5). B: Fibronectin (3.8 nM) and CatG
(500 nM) were incubated without (lane 2) or with 20 WM of RG1503 (lane 3), RG1150 (lane 4) or RG1192 (lane 5). Laminin (3.8 nM) (A,
lane 1) and ¢bronectin (3.8 nM) (B, lane 1) were loaded as control of electrophoretic migration. The molecular mass of the marker proteins
(M) are shown in kDa.
Scheme 2.
1 i was determined by acidimetric titration for CH2COOH and
SO3H content before and after complete acidi¢cation of the polymer
using an amberlite column. As control, we determined i for heparin
according to the same protocol and, as previously described [30], a
value of i=0.8 was found.
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and RG1192, the ionic strength dependence of the equilibrium
dissociation constants Ki was thoroughly di¡erent to that ob-
served with RG1503. Indeed, the presence of benzylamide
groups fully abolished the ionic interactions between the poly-
mer and the enzyme, as evidenced by the negative slope of the
curves shown in Fig. 3. Moreover, a 10-fold increase in ionic
strength leads to a 13-fold decrease in the Ki of RG1150^
CatG and RG1192^CatG complexes (Kiðnon-ionicÞ =120 pM
for both compounds). It is interesting to note that O-butyr-
ylation of heparin a¡ects the heparin^CatG interaction in a
way similar to that observed with our benzylamided RGTA
compounds [32]. Taken together, these results suggest than
CatG no longer binds electrostatically with RG1150 and
RG1192 and that their binding with the enzyme is mainly
governed by non-ionic interactions. Interestingly, CatG con-
tains a shallow hydrophobic pocket which borders the active
site of the enzyme [29]. This hydrophobic surface depression
may then make non-ionic interactions with benzylamide
groups of the polymers and thus could act as additional hy-
drophobic binding site. From these results, we then speculate
that in the benzylamided RGTA^CatG complexes, ionic in-
teractions brought by sulfate and/or carboxylate groups serve
as guides for the formation of an initial complex which then
isomerizes into a stable complex in which the partners are
held together by non-ionic interactions. Such a combination
of ionic and non-ionic interactions which could take place
during the complex formation may thus account for the
very high a⁄nity of these inhibitors toward CatG and for
their ability to form tight complexes with the enzyme.
3.4. E¡ect of RGTA on the CatG-mediated ¢bronectin and
laminin proteolysis
Dextran derivatized such as RG1192 and RG1503 were
shown to promote tissue remodeling in various in vivo models
[2^7]. Based on their in vitro properties, we proposed that
these biopolymers could protect heparin binding growth fac-
tors as well as ECM components from proteolysis mediated
by proteinases activated during the in£ammatory process
[9,11,12]. To further support this hypothesis, we studied the
in vitro e¡ect of RG1503, RG1150 and RG1192 on the CatG-
mediated proteolysis of ¢bronectin and laminin, the major
non-collagenous components of ECM and basement mem-
branes. SDS^PAGE analyses followed by immunoblotting as-
says showed that laminin was e⁄ciency cleaved by CatG, as
evidenced by the disappearance of the 400-kDa and 200-kDa
laminin chains (Fig. 4A, lane 2). In the presence of each
RGTA, however, laminin is protected completely from cleav-
age by CatG (Fig. 4A, lanes 3^5). When the same experiment
was done with ¢bronectin as the natural substrate (Fig. 4B),
all RGTA tested were also able to prevent its CatG-mediated
proteolysis (Fig. 4B, lanes 3^5). However, no complete inhi-
bition of this natural substrate against proteolysis was at-
tained even for concentrations up to 20 WM (data not shown).
4. Concluding remarks
In this study, we provide in vitro evidence that some dex-
tran derivatives could contribute to the regulation of CatG
activity as evidenced by their ability to inhibit its enzymatic
activity toward synthetic as well as natural substrates. We
show that the extent of inhibition varied with the nature of
the substituted groups and revealed that a combination of
both anionic and hydrophobic groups yielded to a very e⁄-
cient inhibitor. Kinetic studies indicate that at physiologic
ionic strength, the best CatG inhibitor (RG1192) has a Ki
value of 0.11 nM, a value lower or far lower than those
previously reported for CatG reversible inhibitors [15,22^28].
Interestingly, while RG1150 and RG1192 inhibited CatG ac-
tivity and protected matrix proteins from proteolysis in a
similar way, only RG1192 presented in vivo tissue repair ac-
tivity. This indicates that CatG inhibition is not involved as a
key or unique mechanism of action of these compounds and
points out the very high degree of complexity and the numer-
ous factors involved in tissue healing.
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